Ratio of platelet reduction is an early predictive factor for the effectiveness of leukocytapheresis for ulcerative colitis patients

Therapeutic Apheresis and Dialysis

Volumn 13, Issue 1, 2009, Pages 6-13

  Takemoto, Koji ^a   Kuriyama, Motoaki ^a   Kato, Jun ^a   Suzuki, Hideyuki ^a   Ishikawa, Shin ^a   Hiraoka, Sakiko ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Leukocytapheresis; Platelet removal; Ulcerative colitis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; LEUKAPHERESIS; LEUKOCYTE COUNT; MALE; PREDICTION; PRIORITY JOURNAL; REMISSION; THERAPY EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; FEMALE; HUMANS; LEUKAPHERESIS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PLATELET COUNT; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 62149089444     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00649.x     Document Type: Article

References (23)

1. Sawada K, Kusugami K, Suzuki Y et al. Leukocytapheresis is ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005 100 : 1362 9.
2. Nishioka C, Aoyama N, Maekawa S et al. Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J Gastroenterol Hepatol 2005 20 : 1567 71.
3. Sawada K, Muto T, Shimoyama T et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003 9 : 307 21.
4. Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis 2006 12 : 15 21.
5. Andoh A, Ogawa A, Kitamura K et al. Suppression of interleukin-1β- and tumor necrosis factor-α-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol 2004 39 : 1150 57.
6. Mitsuyama K, Suzuki A, Matsumoto S et al. Diminished cytokine signaling against bacterial components in mononuclear leukocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol 2005 141 : 130 40.
7. Yamaji K, Yang K, Tsuda H, Hashimoto H. Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. Ther Apher 2002 6 : 402 12.
8. Yamaji K, Onuma S, Yasuda M, Kanai Y, Tsuda H, Takasaki Y. Fluctuations in peripheral blood leukocyte and platelet counts and leukocyte recruitment with large volume leukocytapheresis in healthy volunteers. Ther Apher Dial 2006 10 : 396 403.
9. Pamuk GE, Vural O, Turgut B, Demir M, Umit H, Tezel A. Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: a comparative study. Am J Hematol 2006 81 : 753 9.
10. Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004 99 : 938 45.
11. Kapsoritakis AN, Koukourakis MI, Sfiridaki A et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001 96 : 776 81.
12. Andoh A, Tsujikawa T, Hata K et al. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol 2005 100 : 2042 8.
13. Fukunaga K, Fukuda Y, Yokoyama Y et al. Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients. J Gastroenterol 2006 41 : 524 32.
14. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Br Med J 1955 2 : 1041 8.
15. Takemoto K, Kato J, Kuriyama M et al. Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liver Dis 2007 39 : 422 9.
16. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994 330 : 1841 5.
17. Honma T, Sugimura K, Asakura H et al. Leukocytapheresis is effective in inducing but not in maintaining remission in ulcerative colitis. J Clin Gastroentertol 2005 39 : 886 90.
18. Yagi Y, Andoh A, Inatomi O et al. Modulation of platelet aggregation responses by leukocytapheresis therapy in patients with active ulcerative colitis. J Gastroenterol 2006 41 : 540 6.
19. Saniabadi AR, Hanai H, Takeuchi K et al. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003 7 : 48 59.
20. Shimoyama T, Sawada K, Hiwatashi N et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001 16 : 1 9.
21. Saniabadi AR, Hanai H, Fukunaga K et al. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci 2007 37 : 191 200.
22. Hanai H, Watanabe F, Takeuchi K et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003 1 : 28 35.
23. Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004 36 : 811 7.